99 related articles for article (PubMed ID: 25184174)
1. What price for a cure?
Taylor LE
R I Med J (2013); 2014 Jul; 97(7):16-8. PubMed ID: 25184174
[No Abstract] [Full Text] [Related]
2. Importation of generic hepatitis C therapies: bridging the gap between price and access in high-income countries.
Ghinea N; Lipworth W; Day R; Hill A; Dore GJ; Danta M
Lancet; 2017 Mar; 389(10075):1268-1272. PubMed ID: 27832868
[No Abstract] [Full Text] [Related]
3. MSF pushes down price of generic hepatitis C drugs to new low level.
Wise J
BMJ; 2017 Nov; 359():j5054. PubMed ID: 29092825
[No Abstract] [Full Text] [Related]
4. Indian hepatitis C drug patent decision shakes public health community.
't Hoen EFM
Lancet; 2016 Jun; 387(10035):2272-2273. PubMed ID: 27238944
[No Abstract] [Full Text] [Related]
5. [Costs of modern treatment of chronic hepatitis C].
Stiefelhagen P; Sarrazin C
Med Monatsschr Pharm; 2015 Sep; 38(9):347-9. PubMed ID: 26731852
[No Abstract] [Full Text] [Related]
6. Only just the beginning of the end of hepatitis C.
Lancet; 2014 Jan; 383(9914):281. PubMed ID: 24461110
[No Abstract] [Full Text] [Related]
7. Hepatitis C: global ambition, national realities.
Lancet; 2016 May; 387(10032):1970. PubMed ID: 27203752
[No Abstract] [Full Text] [Related]
8. Treatment strategy for hepatitis C: a dilemma for the payers and the providers.
Haque M; Zariat A
Am J Gastroenterol; 2014 Dec; 109(12):1953-4. PubMed ID: 25470586
[No Abstract] [Full Text] [Related]
9. Q & A with Karen Tashima, MD new direct-acting antiviral agents offer therapeutic revolution for hepatitis C virus infection.
Korr M
R I Med J (2013); 2014 Jul; 97(7):29-30. PubMed ID: 24983018
[No Abstract] [Full Text] [Related]
10. [Naturopathy consultation. Soon all patients will be curable. Decisive breakthrough in therapy of hepatitis C ].
Einecke D
MMW Fortschr Med; 2014 Feb; 156(3):26-7. PubMed ID: 24938054
[No Abstract] [Full Text] [Related]
11. Effectiveness, costs weigh on HCV treatment decisions.
Traynor K
Am J Health Syst Pharm; 2014 Jul; 71(14):1156-7. PubMed ID: 24973370
[No Abstract] [Full Text] [Related]
12. [Economic evaluation of combined therapy in chronic hepatitis C].
Casado MA; Buti M; Fosbrook L; Esteban R
Gastroenterol Hepatol; 2000 Feb; 23 Suppl 1():57-62. PubMed ID: 11968346
[No Abstract] [Full Text] [Related]
13. Pharmaceuticals. Advocates protest the cost of a hepatitis C cure.
Cohen J
Science; 2013 Dec; 342(6164):1302-3. PubMed ID: 24337268
[No Abstract] [Full Text] [Related]
14. Doing battle with HCV.
Fimmel CJ
Am J Gastroenterol; 2000 Mar; 95(3):582-3. PubMed ID: 10710043
[No Abstract] [Full Text] [Related]
15. [Access to hepatitis C treatment: a lesson for the future.].
Craxì L
Recenti Prog Med; 2018 Jan; 109(1):25-27. PubMed ID: 29451518
[TBL] [Abstract][Full Text] [Related]
16. A world without hepatitis C.
Ryder S; Dillon J
Health Serv J; 2014 May; 124(6397):21-3. PubMed ID: 25033511
[No Abstract] [Full Text] [Related]
17. 'HepConomics': cost-effective, indeed, but how can we pay for it?
Athanasakis K; Petrakis I; Kyriopoulos J
J Viral Hepat; 2015 Aug; 22(8):682. PubMed ID: 25727161
[No Abstract] [Full Text] [Related]
18. Sticker shock and the price of new therapies for hepatitis C: is it worth it?
Reau NS; Jensen DM
Hepatology; 2014 Apr; 59(4):1246-9. PubMed ID: 24493069
[No Abstract] [Full Text] [Related]
19. Economics of chronic hepatitis B and hepatitis C.
Rajendra A; Wong JB
J Hepatol; 2007 Oct; 47(4):608-17. PubMed ID: 17697724
[TBL] [Abstract][Full Text] [Related]
20. Generic medications for hepatitis C.
Jensen DM; Sebhatu P; Reau NS
Liver Int; 2016 Jul; 36(7):925-8. PubMed ID: 27306302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
